ArriVent BioPharma (AVBP) Stock Forecast: StockMap's 2-Week Call
AVBP stock forecast: StockMap's model leans Underperform on ArriVent BioPharma for the two weeks after the Nov 19 close, toward AVBP trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 5 of 6 two-week windows on AVBP since Aug 21; by chance, a call on the same dates was right 58% of the time.
ArriVent BioPharma last closed at $11.26, +3.30% on the session.
Against the IVW growth benchmark the position is +5.63% over the forecast window.
ArriVent BioPharma's market cap is $582.39M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -36 (too close to call).
Where AVBP sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 4 bullish and 11 bearish.
Agreement across those insights is 73%.
45 daily calls for AVBP so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks ArriVent BioPharma in the 18th percentile on return on equity, where 100 is best.
ArriVent BioPharma is classified under Health Care / Biotechnology.
StockMap tracks ArriVent BioPharma as the 164th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite ArriVent BioPharma ranks 271st of 394 in the group, against a group median of -0.27.